ablation-scar we compared DE-MRI before and after Cryoballoon ablation on the basis that a predictable antral lesion set would be created. The method was subsequently used in patients undergoing radiofrequency or cryoballoon ablation. Endocardial voltage was measured and compared with corresponding enhancement levels on DE-MRI. Pre and post ablation enhancement was then compared with clinical outcome and risk factors for stroke.

**Methods** Pre-ablation DE-MRI was performed in 50 patients from two centres, undergoing pulmonary vein isolation; 25 with Arctic Front cryoballoon and 25 with conventional circumferential pulmonary vein ablation. Post-ablation DE-MRI was performed at 3 months. 10 patients at the pulmonary vein ablation. Post-ablation DE-MRI was performed at two centres, undergoing pulmonary vein isolation; 25 with Arctic Front cryoballoon and 25 with conventional circumferential pulmonary vein ablation. Post-ablation DE-MRI was performed at 3 months. 10 patients at the first procedure and 12 patients returning for a redo procedure underwent endocardial voltage mapping with registration to MRA segmentation for comparison with the DE-MRI. The free-breathing late gadolinium enhanced sequence was also registered to the MRA segmentation and surface intensities were normalised using mean intensity of the blood pool (BIP). Normalised intensity levels were projected onto LA surface as multiples of SD above BIP mean.

**Results** Ostial and LA intensity were similar in pre ablation scans and greater in the ostia in post ablation scans (p=0.48 and p<0.001 respectively). Bipolar voltage measurements were compared for each intensity level. No significant differences were noted between SD 0 and 1, however significant difference were noted between SD 1 and 2 (1.41±0.03 vs 1.26±0.04 mV p<0.001), SD 2 and 3, (1.26±0.04 vs 0.90±0.05 mV p<0.001), SD 3 and 4 (0.90±0.05 vs 0.65±0.04 mV p<0.001) and SD 4 and 5, (0.65±0.04 vs 0.45±0.05 p=0.004). No significant differences were found between intensities >SD 5. Intensity >SD 3 was identified as low voltage atrial tissue <1 mV (scar). % scar was higher in patients with high risk of stroke (CHADS2 >1) compared to low (CHADS2=0), (low vs high 3.19±3.17% vs 7.13±7.38% p=0.035), % scar was also greater in pre ablation scans from patients with AF recurrence vs none following ablation (6.6±6.7% vs 3.5±3.0% p=0.032).

**Conclusion** We have demonstrated the feasibility of an objective, automated method of DE-MRI analysis of left atrial ablation-scar. Atrial enhancement is reflective of endocardial low-voltage myocardium over a range of intensities and voltages. Pre-ablation atrial scar identified patients at higher risk of stroke and reduced success from AF ablation, suggesting potential future roles for DE-MRI in the management of patients with AF.

**051** ORGANISATIONAL INDEX IS THE BEST ASSESSMENT OF FRACTIONATION IN PERSISTENT ATRIAL FIBRILLATION: ANALYTIC COMPARISONS AND ABLATION RESULTS
doi:10.1136/heartjnl-2012-301877b.51

1M C Finlay,* 2B Lim, 2J McCready, 3S Ahsan, 2A B Gopalmurugan, 3L Xu, 3O Segal, 2M Lowe, 2P D Lambiase. 1UCL, The Heart Hospital, UK; 2UCLH, UK; 3UCL, UK

**Introduction** Targeting fractionated electrogroms (EGMs) is commonly used in catheter ablation (CA) of persistent atrial fibrillation (PersAF). Several automatic algorithms exist to identify sites of fractionation. EGMs exhibiting continuous activity (ContA) and a high organisation index (OI) have also been proposed as features of significant sites. We investigated five indices of fractionation to assess the consistency of signal classification, and associated the effects of ablation lesions to these classification techniques.

**Methods** 16 patients undergoing first-time CA of persAF were studied. A NavX CFAE map was acquired after circumferential pulmonary vein isolation. EGM data were exported and analysed in custom software. CA was performed on sites showing high ContA. Offline analysis compared 5 algorithms: ContA, OI, Dominant Frequency (DF), CFAEmean (NavX equivalent) and shortest complex interval (SCI, Carto equivalent) after signal screening. The effect of ablation lesions on AF cycle length was correlated with underlying fractionation.

**Results** CA on ContA sites terminated AF in 50% cases. 2589 8-s EGMs and 471 ablation lesions targeting fractionation were analysed. Varying the refractory periods (RP) of algorithms produced large changes in signal classification for CFAEmean (Pearson R=0.81±0.05 for 10 ms variation in RP, R=0.08 for 90 ms variation in RP) and SCI (R=0.95±0.04 for 10 ms, R=−0.34 for 90 ms), whereas ContA was unaffected (R=0.99±0.01 for 10 ms, R=0.80 for
Methods

Introduction

Reports of the prevalence of left atrial appendage (LAA) thrombus was identified in 3 patients from 586 (0.5%) undergoing catheter ablation for atrial fibrillation (AF) vary and may depend on the anticoagulation regime used prior to the procedure.

Methods We undertook transoesophageal echocardiograms (TOE) in 586 patients (age 59.9±4.0 years old, mean±SE, 64.5% male) undergoing catheter ablation for AF who were anti-coagulated on warfarin (international normalised ratio 2–3) for at least 3 consecutive weeks prior to procedure and maintained on warfarin for the procedure itself.

Results LAA thrombus was identified in 3 patients from 586 (0.5%) despite all 3 having therapeutic INRs (2.2, 2.2 and 3.3 respectively). None of the remaining patients had a peri-procedural stroke. The three patients with LAA thrombus had CHADS2 scores of ≥1 and CHA2DS2-VASc scores of ≥2. All three patients had impaired left ventricular systolic function (LVSF), and LAA emptying velocities of <40 cm/s (23, 29 and 31 cm/s). Patients with LAA emptying velocities <40 cm/s on TOE (n=111) had significantly (p<0.05) higher CHADS2 (0.9±0.1 vs 0.7±0.001) and CHA2DS2-VASc scores (1.7±0.1 vs 1.4±0.1), and larger LA diameter (4.95±0.09 vs 4.38±0.05 cm, OR for LA >4.6 cm: 2.4, 95% CI 2.13 to 5.51), and were more likely to have impaired LVSF (OR: 2.66, 95% CI 1.52 to 4.66) compared to those with higher velocities on multivariate analysis.

Conclusions The prevalence of LAA thrombus using our anti-coagulation regime is extremely low. Providing patients have been therapeutically anti-coagulated, pre-operative TOE need only be performed in patients with a CHADS2 score of ≥1/CHA2DS2-VASc score of ≥2 or when LA diameter is >4.6 cm. This criteria has the highest sensitivity (84%) for identifying LAA velocities of <40 cm/s as well as having a sensitivity of 100% for identifying thrombus and also would reduce the number of TOEs performed by 27.7%.

Abstract 051 Figure 1

THE PREVALENCE OF LEFT ATRIAL APPENDAGE THROMBUS IN PATIENTS UNDERGOING CATHETER ABLATION FOR ATRIAL FIBRILLATION MAINTAINED ON WARFARIN

doi:10.1136/heartjnl-2012-301877b.52

Factors affecting quality of Warfarin anticoagulation in patients with atrial fibrillation: insights from AFFIRM

doi:10.1136/heartjnl-2012-301877b.53

The prevalence of left atrial appendage thrombus was identified in 3 patients from 586 (0.5%) despite all 3 having therapeutic INRs (2.2, 2.2 and 3.3 respectively). None of the remaining patients had a peri-procedural stroke. The three patients with LAA thrombus had CHADS2 scores of ≥1 and CHA2DS2-VASc scores of ≥2. All three patients had impaired left ventricular systolic function (LVSF), and LAA emptying velocities of <40 cm/s (23, 29 and 31 cm/s). Patients with LAA emptying velocities <40 cm/s on TOE (n=111) had significantly (p<0.05) higher CHADS2 (0.9±0.1 vs 0.7±0.001) and CHA2DS2-VASc scores (1.7±0.1 vs 1.4±0.1), and larger LA diameter (4.95±0.09 vs 4.38±0.05 cm, OR for LA >4.6 cm: 2.4, 95% CI 2.13 to 5.51), and were more likely to have impaired LVSF (OR: 2.66, 95% CI 1.52 to 4.66) compared to those with higher velocities on multivariate analysis.

Conclusions The prevalence of LAA thrombus using our anti-coagulation regime is extremely low. Providing patients have been therapeutically anti-coagulated, pre-operative TOE need only be performed in patients with a CHADS2 score of ≥1/CHA2DS2-VASc score of ≥2 or when LA diameter is >4.6 cm. This criteria has the highest sensitivity (84%) for identifying LAA velocities of <40 cm/s as well as having a sensitivity of 100% for identifying thrombus and also would reduce the number of TOEs performed by 27.7%.

THE AFFIRM TRIAL

Introduction

The efficacy of warfarin anticoagulation in atrial fibrillation patients at risk for stroke is related to time in therapeutic range (TTR) with an INR 2.0–3.0. Factors predisposing to low TTR have not been investigated comprehensively.

Methods

This post hoc analysis of the AFFIRM trial included patients with at least five INR values. “Optimal” anticoagulation was defined as TTR ≥75%; above this level, adjusted-dose warfarin offers the same prognostic benefits as new oral anticoagulants. Binary regression analysis identified independent variables associated with TTR. The impact of TTR on outcomes was assessed further through cox regression analysis.

Results

Of 3066 AFFIRM patients, the median TTR was 0.62 SD 0.2. 975 patients (32%) were “optimally” anticoagulated. These subjects were more frequently male, treated with rate control alone and were less likely to have heart failure, diabetes, myocardial infarction, and hepatic or renal failure (all p<0.05). Cox regression analysis demonstrated TTR was a major determinant of all cause mortality (p<0.001), ischaemic stroke or TIA (p=0.003) and major bleeding (p=0.01). Binary regression analysis revealed female gender (p=0.005), minority status (p=0.001), history of myocardial infarction (p=0.02) and non-treatment with β blockers (p<0.001) were independently associated with low TTR.

Conclusion

TTR is related strongly to clinical outcomes. TTR is associated with clinical and demographic characteristics. Knowledge of factors associated with low TTR may help better optimise antithrombotic management.